Aspirin

Use of low-dose aspirin yielded a low risk of venous thromboembolism and medication-associated complications after primary shoulder arthroplasty, according to results presented at the American Shoulder and Elbow Surgeons Annual Meeting.

For patients with chronic hepatitis B, aspirin therapy correlated with a reduced risk for hepatocellular carcinoma, according to a presenter at The Liver Meeting Digital Experience.

In new data from the THALES trial of patients with prior stroke, the benefit of ticagrelor plus aspirin for secondary stroke prevention was greatest in those with ipsilateral atherosclerotic stenosis.

One month of dual antiplatelet therapy followed by aspirin monotherapy after PCI with a polymer-free drug-coated stent was noninferior to 6 to 12 months of DAPT after PCI with a contemporary drug-eluting stent, researchers reported.

Adults at intermediate CV risk assigned a polypill plus aspirin were 31% less likely to experience a CV event or death compared with those assigned double placebo over a nearly 5-year period, according to new data from the TIPS-3 trial.

AstraZeneca announced the FDA approved its P2Y12 inhibitor ticagrelor for the reduction of stroke risk among patients with acute ischemic stroke or high-risk transient ischemic attack.

Saphenous vein graft occlusion, graft failure and bleeding with aspirin plus ticagrelor (Brilinta, AstraZeneca) after CABG compared with aspirin alone.

Net adverse clinical events in patients who underwent PCI for ACS according to aspirin-prasugrel (Effient, Daiichi Sankyo/Eli Lilly) strategy.

Among patients with diabetes and stable CAD, ticagrelor plus aspirin reduced ischemic limb events compared with aspirin alone, according to new data from the THEMIS randomized controlled trial.

Among patients who underwent PCI for ACS and then had dual antiplatelet therapy with aspirin and prasugrel, halving the prasugrel dose after 1 month conferred reduced risk for net adverse clinical events, researchers reported.